# STAT5B

## Overview
STAT5B is a gene that encodes the protein signal transducer and activator of transcription 5B (STAT5B), which is a member of the STAT family of transcription factors. STAT5B plays a pivotal role in mediating cellular responses to cytokines and growth factors, particularly in the immune system and during growth processes. As a transcription factor, STAT5B is activated through phosphorylation, leading to its dimerization and subsequent translocation to the nucleus, where it regulates the expression of target genes involved in cell proliferation, differentiation, and survival (Kanai2012The; Smith2023STAT5b:). The protein is crucial for the development and function of various immune cells, including T cells and natural killer cells, and is a key mediator of growth hormone signaling, influencing postnatal growth and development (Hwa2021Human; VargasHernández2020Human). Mutations in the STAT5B gene can lead to significant clinical conditions, such as growth hormone insensitivity and immune dysfunctions, highlighting its essential role in human health (Hwa2021Human; Klammt2018Dominantnegative).

## Structure
The STAT5B protein is a member of the STAT family, which plays a crucial role in cellular processes such as growth, differentiation, apoptosis, and proliferation. The primary structure of STAT5B includes several domains: the coiled-coil domain, DNA binding domain, linker domain, SH2 domain, N-terminal domain, and transactivation domain (HaasNeill2024The). The SH2 domain is particularly important for stabilizing the parallel dimer form, with the phosphotyrosine (pY) residue interacting with the pY pocket of the conjugate protomer, forming the basis of the parallel dimer interface (HaasNeill2024The).

The secondary structure of the SH2 domain consists of a central anti-parallel β-sheet flanked by α-helices, forming two subpockets: the pY (phosphate-binding) and pY+3 (specificity) pockets (de2019Structural). The tertiary structure involves the folding of these domains, with the SH2 domain playing a critical role in protein regulation and activation (de2019Structural).

Quaternary structure involves the dimerization of STAT5B upon activation, which is essential for its function in signal transduction pathways (de2019Structural). Post-translational modifications, such as phosphorylation, are crucial for the activation and nuclear accumulation of phosphorylated STAT dimers, driving transcription (de2019Structural). The N642H mutation in the SH2 domain is associated with aggressive leukemia and enhances the stability of the active parallel dimer state, leading to hyperactivation (HaasNeill2024The).

## Function
STAT5B is a transcription factor that plays a critical role in cytokine signaling pathways, particularly in the immune system and hematopoiesis. It is activated by phosphorylation in response to cytokines and growth factors, such as interleukins and growth hormone (GH). Upon activation, STAT5B forms dimers and translocates to the nucleus, where it regulates the transcription of genes involved in cell proliferation, differentiation, and survival (Kanai2012The; Smith2023STAT5b:).

In immune cells, STAT5B is essential for the development and function of various lymphocyte subsets, including CD8+ T cells, regulatory T cells (Tregs), and natural killer (NK) cells. It is a key downstream effector of IL-2 and IL-15 signaling, crucial for NK cell activation and maturation (VargasHernández2020Human; Smith2023STAT5b:). STAT5B also influences B cell development through IL-7R signaling, promoting cell survival and immunoglobulin gene rearrangement (Smith2023STAT5b:).

In the context of growth, STAT5B mediates GH signaling, which is vital for postnatal growth and development. It regulates the transcription of genes such as IGF1, which is crucial for growth hormone-induced IGF-1 production (Hwa2021Human; Hennighausen2008Interpretation). Deficiencies in STAT5B can lead to growth hormone insensitivity and immunodeficiency, underscoring its importance in maintaining normal growth and immune function (Hwa2021Human; Kanai2012The).

## Clinical Significance
Mutations in the STAT5B gene are associated with a range of clinical conditions, primarily affecting growth and immune function. Autosomal recessive mutations in STAT5B lead to growth hormone insensitivity (GHI) syndromes, characterized by severe insulin-like growth factor I (IGF-I) deficiency and significant postnatal growth failure. These mutations also result in immune dysfunctions, such as severe eczema, autoimmune thyroiditis, and chronic pulmonary disease, with some cases progressing to lung fibrosis and respiratory failure (Hwa2021Human).

Dominant-negative mutations in STAT5B cause milder forms of GHI, with symptoms including growth impairment, elevated IgE levels, and eczema. These mutations interfere with the normal function of STAT5B by affecting nuclear localization and DNA binding, leading to mild immune dysregulation (Klammt2018Dominantnegative).

Certain STAT5B mutations are linked to hematological malignancies. For instance, the N642H mutation is frequently detected in pediatric T-cell acute lymphoblastic leukemia and is associated with increased recurrence risk. This mutation, along with others like Y665F, contributes to aggressive forms of leukemia and myeloid neoplasms (Hwa2021Human; Kim2022Genomic). These findings underscore the critical role of STAT5B in both growth regulation and immune system function.

## Interactions
STAT5B is a transcription factor that participates in various protein-protein and protein-DNA interactions. It interacts with the growth hormone receptor (GHR) at specific tyrosine motifs, namely Y534, Y566, and Y627, which are crucial for its recruitment and activation. These interactions facilitate the binding of STAT5B to DNA, promoting gene transcription (Uyttendaele2007Mammalian).

STAT5B also interacts with the coactivator p300/CBP, enhancing prolactin-induced transcriptional activation. This interaction involves the transactivation domain of STAT5B and is necessary for its transcriptional activity. However, STAT5B can also inhibit glucocorticoid receptor (GR)-mediated transcription, potentially through complex formation with GR rather than competition for p300/CBP (Pfitzner1998p300CREBBinding).

In addition, STAT5B is involved in inhibitory interactions with nuclear factor kappa B (NFκB) signaling. It does not directly bind NFκB but inhibits its signaling by competing for coactivators like p300/CBP, highlighting its role in modulating transcriptional responses through protein-protein interactions (Luo2000Stat5b).


## References


[1. (Luo2000Stat5b) Guoyang Luo and Li-yuan Yu-Lee. Stat5b inhibits nfκb-mediated signaling. Molecular Endocrinology, 14(1):114–123, January 2000. URL: http://dx.doi.org/10.1210/MEND.14.1.0399, doi:10.1210/mend.14.1.0399. This article has 115 citations.](https://doi.org/10.1210/MEND.14.1.0399)

[2. (Kanai2012The) Takahiro Kanai, Jennifer Jenks, and Kari Christine Nadeau. The stat5b pathway defect and autoimmunity. Frontiers in Immunology, 2012. URL: http://dx.doi.org/10.3389/fimmu.2012.00234, doi:10.3389/fimmu.2012.00234. This article has 99 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2012.00234)

[3. (de2019Structural) Elvin D. de Araujo, Anna Orlova, Heidi A. Neubauer, Dávid Bajusz, Hyuk-Soo Seo, Sirano Dhe-Paganon, György M. Keserű, Richard Moriggl, and Patrick T. Gunning. Structural implications of stat3 and stat5 sh2 domain mutations. Cancers, 11(11):1757, November 2019. URL: http://dx.doi.org/10.3390/cancers11111757, doi:10.3390/cancers11111757. This article has 55 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers11111757)

[4. (VargasHernández2020Human) Alexander Vargas-Hernández, Agnieszka Witalisz-Siepracka, Michaela Prchal-Murphy, Klara Klein, Sanjana Mahapatra, Waleed Al-Herz, Emily M. Mace, Alexandre F. Carisey, Jordan S. Orange, Veronika Sexl, and Lisa R. Forbes. Human signal transducer and activator of transcription 5b (stat5b) mutation causes dysregulated human natural killer cell maturation and impaired lytic function. Journal of Allergy and Clinical Immunology, 145(1):345-357.e9, January 2020. URL: http://dx.doi.org/10.1016/j.jaci.2019.09.016, doi:10.1016/j.jaci.2019.09.016. This article has 25 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.jaci.2019.09.016)

[5. (Kim2022Genomic) Uijin Kim and Ha Youn Shin. Genomic mutations of the stat5 transcription factor are associated with human cancer and immune diseases. International Journal of Molecular Sciences, 23(19):11297, September 2022. URL: http://dx.doi.org/10.3390/ijms231911297, doi:10.3390/ijms231911297. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms231911297)

[6. (Uyttendaele2007Mammalian) Isabel Uyttendaele, Irma Lemmens, Annick Verhee, Anne-Sophie De Smet, Joël Vandekerckhove, Delphine Lavens, Frank Peelman, and Jan Tavernier. Mammalian protein-protein interaction trap (mappit) analysis of stat5, cis, and socs2 interactions with the growth hormone receptor. Molecular Endocrinology, 21(11):2821–2831, November 2007. URL: http://dx.doi.org/10.1210/ME.2006-0541, doi:10.1210/me.2006-0541. This article has 57 citations.](https://doi.org/10.1210/ME.2006-0541)

[7. (Pfitzner1998p300CREBBinding) Edith Pfitzner, Ruth Jähne, Manuela Wissler, Elisabeth Stoecklin, and Bernd Groner. P300/creb-binding protein enhances the prolactin-mediated transcriptional induction through direct interaction with the transactivation domain of stat5, but does not participate in the stat5-mediated suppression of the glucocorticoid response. Molecular Endocrinology, 12(10):1582–1593, October 1998. URL: http://dx.doi.org/10.1210/mend.12.10.0180, doi:10.1210/mend.12.10.0180. This article has 140 citations.](https://doi.org/10.1210/mend.12.10.0180)

[8. (Hwa2021Human) Vivian Hwa. Human growth disorders associated with impaired gh action: defects in stat5b and jak2. Molecular and Cellular Endocrinology, 519:111063, January 2021. URL: http://dx.doi.org/10.1016/j.mce.2020.111063, doi:10.1016/j.mce.2020.111063. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.mce.2020.111063)

[9. (Hennighausen2008Interpretation) Lothar Hennighausen and Gertraud W. Robinson. Interpretation of cytokine signaling through the transcription factors stat5a and stat5b. Genes &amp; Development, 22(6):711–721, March 2008. URL: http://dx.doi.org/10.1101/gad.1643908, doi:10.1101/gad.1643908. This article has 284 citations.](https://doi.org/10.1101/gad.1643908)

[10. (Klammt2018Dominantnegative) Jürgen Klammt, David Neumann, Evelien F. Gevers, Shayne F. Andrew, I. David Schwartz, Denise Rockstroh, Roberto Colombo, Marco A. Sanchez, Doris Vokurkova, Julia Kowalczyk, Louise A. Metherell, Ron G. Rosenfeld, Roland Pfäffle, Mehul T. Dattani, Andrew Dauber, and Vivian Hwa. Dominant-negative stat5b mutations cause growth hormone insensitivity with short stature and mild immune dysregulation. Nature Communications, May 2018. URL: http://dx.doi.org/10.1038/s41467-018-04521-0, doi:10.1038/s41467-018-04521-0. This article has 79 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-018-04521-0)

11. (HaasNeill2024The) The structural influence of the oncogenic driver mutation N642H in the STAT5B SH2 domain. This article has 0 citations.

[12. (Smith2023STAT5b:) Madison R. Smith, Lisa R. Forbes Satter, and Alexander Vargas-Hernández. Stat5b: a master regulator of key biological pathways. Frontiers in Immunology, January 2023. URL: http://dx.doi.org/10.3389/fimmu.2022.1025373, doi:10.3389/fimmu.2022.1025373. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2022.1025373)